JP2006515227A - 十字流濾過の方法およびそのための装置 - Google Patents
十字流濾過の方法およびそのための装置 Download PDFInfo
- Publication number
- JP2006515227A JP2006515227A JP2004568846A JP2004568846A JP2006515227A JP 2006515227 A JP2006515227 A JP 2006515227A JP 2004568846 A JP2004568846 A JP 2004568846A JP 2004568846 A JP2004568846 A JP 2004568846A JP 2006515227 A JP2006515227 A JP 2006515227A
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- milk
- filtration
- flow rate
- flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 181
- 238000009295 crossflow filtration Methods 0.000 title claims abstract description 61
- 238000001914 filtration Methods 0.000 claims abstract description 92
- 239000012528 membrane Substances 0.000 claims description 226
- 235000013336 milk Nutrition 0.000 claims description 152
- 239000008267 milk Substances 0.000 claims description 152
- 210000004080 milk Anatomy 0.000 claims description 152
- 239000012466 permeate Substances 0.000 claims description 128
- 238000001471 micro-filtration Methods 0.000 claims description 105
- 108090000623 proteins and genes Proteins 0.000 claims description 73
- 239000012465 retentate Substances 0.000 claims description 72
- 230000008569 process Effects 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 40
- 239000000706 filtrate Substances 0.000 claims description 37
- 238000011026 diafiltration Methods 0.000 claims description 33
- 238000000108 ultra-filtration Methods 0.000 claims description 32
- 238000000746 purification Methods 0.000 claims description 25
- 239000000919 ceramic Substances 0.000 claims description 24
- 239000011148 porous material Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 15
- 238000005194 fractionation Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 229960000074 biopharmaceutical Drugs 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 230000007704 transition Effects 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 2
- 230000009897 systematic effect Effects 0.000 claims 4
- 239000012670 alkaline solution Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims 2
- 239000012266 salt solution Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 16
- 238000000926 separation method Methods 0.000 abstract description 15
- 238000009434 installation Methods 0.000 abstract description 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 56
- 239000000047 product Substances 0.000 description 55
- 239000000523 sample Substances 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 29
- 238000004140 cleaning Methods 0.000 description 27
- 230000009261 transgenic effect Effects 0.000 description 27
- 238000012545 processing Methods 0.000 description 24
- 108010076119 Caseins Proteins 0.000 description 23
- 239000007788 liquid Substances 0.000 description 22
- 102000011632 Caseins Human genes 0.000 description 21
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 239000005018 casein Substances 0.000 description 15
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 15
- 235000021240 caseins Nutrition 0.000 description 15
- 238000001155 isoelectric focusing Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000011084 recovery Methods 0.000 description 14
- 230000000717 retained effect Effects 0.000 description 14
- 241000283707 Capra Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 238000001542 size-exclusion chromatography Methods 0.000 description 11
- 235000011121 sodium hydroxide Nutrition 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000010408 film Substances 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000000356 contaminant Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102000004407 Lactalbumin Human genes 0.000 description 5
- 108090000942 Lactalbumin Proteins 0.000 description 5
- 108010011756 Milk Proteins Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000013618 particulate matter Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000014171 Milk Proteins Human genes 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 235000020251 goat milk Nutrition 0.000 description 4
- 150000002605 large molecules Chemical class 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 235000021241 α-lactalbumin Nutrition 0.000 description 4
- 101000693922 Bos taurus Albumin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 3
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- 102000008192 Lactoglobulins Human genes 0.000 description 3
- 239000005708 Sodium hypochlorite Substances 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- -1 antibodies Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000011021 bench scale process Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000020243 first infant milk formula Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000008234 soft water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000010977 unit operation Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013590 bulk material Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000046101 human AFP Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 238000004262 preparative liquid chromatography Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 230000003134 recirculating effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 235000021247 β-casein Nutrition 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000910039 Bos taurus Alpha-S1-casein Proteins 0.000 description 1
- 101000741059 Bos taurus Alpha-S2-casein Proteins 0.000 description 1
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 1
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 1
- 101001008231 Bos taurus Beta-lactoglobulin Proteins 0.000 description 1
- 101000761239 Bos taurus Kappa-casein Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000693913 Homo sapiens Albumin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001365789 Oenanthe crocata Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710112672 Probable tape measure protein Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101000895752 Rattus norvegicus Alpha-S2-casein-like A Proteins 0.000 description 1
- 101000947125 Rattus norvegicus Beta-casein Proteins 0.000 description 1
- 101000667278 Rattus norvegicus Whey acidic protein Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710204224 Tape measure protein Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000005112 continuous flow technique Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 229960004336 human antithrombin iii Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011070 membrane recovery Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000011041 water permeability test Methods 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Water Supply & Treatment (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44978603P | 2003-02-24 | 2003-02-24 | |
| PCT/US2003/024529 WO2004076695A1 (en) | 2003-02-24 | 2003-08-06 | Methods of tangential flow filtration and an apparatus therefore |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515227A true JP2006515227A (ja) | 2006-05-25 |
| JP2006515227A5 JP2006515227A5 (enExample) | 2006-09-28 |
Family
ID=32927567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004568846A Abandoned JP2006515227A (ja) | 2003-02-24 | 2003-08-06 | 十字流濾過の方法およびそのための装置 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040167320A1 (enExample) |
| EP (1) | EP1601788A4 (enExample) |
| JP (1) | JP2006515227A (enExample) |
| CN (1) | CN1759189A (enExample) |
| AU (1) | AU2003261387A1 (enExample) |
| CA (1) | CA2516836A1 (enExample) |
| RU (1) | RU2005129745A (enExample) |
| WO (1) | WO2004076695A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010533663A (ja) * | 2007-07-17 | 2010-10-28 | エフ．ホフマン−ラ ロシュ アーゲー | 可変的タンジェンシャルフロー濾過 |
| KR20160138949A (ko) * | 2014-02-17 | 2016-12-06 | 바이엘 악티엔게젤샤프트 | 단백질 용액으로부터의 연속식 완충제 또는 배지 교환을 위한 한외여과 장치 |
| JP2017510452A (ja) * | 2014-03-07 | 2017-04-13 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 生物学的生成物の分画のための装置及び方法 |
| JP2021519777A (ja) * | 2018-03-30 | 2021-08-12 | インスメッド インコーポレイテッド | リポソーム医薬品の連続製造方法 |
| US12016873B2 (en) | 2014-05-15 | 2024-06-25 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030005468A1 (en) * | 1998-06-19 | 2003-01-02 | Meade Harry M. | Methods and vectors for improving nucleic acid expression |
| US20040226052A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
| WO2005073732A2 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Lc/ms method of analyzing high molecular weight proteins |
| US20050197496A1 (en) * | 2004-03-04 | 2005-09-08 | Gtc Biotherapeutics, Inc. | Methods of protein fractionation using high performance tangential flow filtration |
| WO2005119126A1 (fr) * | 2004-05-28 | 2005-12-15 | Alstom Technology Ltd | Dispositif a lit fluidise a agent comburant enrichi en oxygene |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| AU2011203578B2 (en) * | 2004-09-30 | 2012-10-11 | Bayer Healthcare Llc | Devices and methods for integrated continuous manufacturing of biological molecules |
| JP5579966B2 (ja) * | 2004-09-30 | 2014-08-27 | バイヤー ヘルスケア エルエルシー | 生体分子の一貫連続製造のための装置及び方法 |
| US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
| US7531632B2 (en) * | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| DK2007506T3 (da) | 2006-03-31 | 2014-06-16 | Danisco Us Inc | Tangentialstrømningsfiltreringsapparater, -systemer og -fremgangsmådertil separering af forbindelser |
| FR2901796A1 (fr) * | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
| FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| US20080160134A1 (en) * | 2006-12-27 | 2008-07-03 | Jamie Allen Hestekin | Method Of Producing Concentrated Liquid Dairy Products |
| FR2910786B1 (fr) | 2006-12-29 | 2017-08-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) | "procede d'extraction d'une proteine presente dans du lait" |
| GB0711327D0 (en) * | 2007-06-12 | 2007-07-25 | Hansa Medical Ab | Diagnostic method |
| JP5205470B2 (ja) * | 2007-11-29 | 2013-06-05 | エフ．ホフマン−ラ ロシュ アーゲー | 免疫グロブリン凝集物 |
| JP5717625B2 (ja) * | 2008-05-14 | 2015-05-13 | アグリカルチャー ヴィクトリア サービス ピーティーワイ エルティーディーＡｇｒｉｃｕｌｔｕｒｅ Ｖｉｃｔｏｒｉａ Ｓｅｒｖｉｃｅｓ Ｐｔｙ Ｌｔｄ | アンギオゲニン濃縮ミルク分画 |
| JP5762951B2 (ja) * | 2008-05-15 | 2015-08-12 | ダブリュ．・ヘルス・エル．ピー．Ｗ． Ｈｅａｌｔｈ Ｌ．Ｐ． | 分泌性免疫グロブリンの豊富な乳画分の製造方法 |
| US9055752B2 (en) | 2008-11-06 | 2015-06-16 | Intercontinental Great Brands Llc | Shelf-stable concentrated dairy liquids and methods of forming thereof |
| CN102191226A (zh) * | 2010-03-08 | 2011-09-21 | 北京清大天一科技有限公司 | 细胞培养混合物的分离纯化方法 |
| UA112972C2 (uk) | 2010-09-08 | 2016-11-25 | Інтерконтінентал Грейт Брендс ЛЛС | Рідкий молочний концентрат з високим вмістом сухих речовин |
| JP6189751B2 (ja) | 2010-12-30 | 2017-08-30 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | 病原体不活性化剤としてのグリコール |
| US8840790B2 (en) * | 2011-04-27 | 2014-09-23 | Fenwal, Inc. | Systems and methods of controlling fouling during a filtration procedure |
| JP6363017B2 (ja) | 2011-09-01 | 2018-07-25 | 中外製薬株式会社 | 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法 |
| EP2885392A1 (en) * | 2012-08-20 | 2015-06-24 | Terumo BCT, Inc. | Concentrating components of fluid circulated through a cell growth chamber |
| BR112015009553A2 (pt) * | 2012-10-30 | 2017-10-03 | Hoffmann La Roche | Método para separar uma proteína de interesse de uma solução de cultura de células |
| US10478543B2 (en) | 2013-01-11 | 2019-11-19 | The Charles Stark Draper Laboratory, Inc. | Systems and methods for increasing convective clearance of undesired particles in a microfluidic device |
| CN104968408B (zh) * | 2013-02-05 | 2019-09-17 | 普凯尔德诊断技术有限公司 | 过滤装置以及使用该过滤装置的方法 |
| JP2016508515A (ja) | 2013-02-13 | 2016-03-22 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用 |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| AU2014285971A1 (en) | 2013-07-05 | 2016-02-04 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
| CN112588116A (zh) | 2014-05-13 | 2021-04-02 | 美国安进公司 | 用于过滤器和过滤过程的过程控制系统和方法 |
| EP3148713B1 (en) * | 2014-05-27 | 2025-02-12 | Artificial Cell Technologies, Inc. | Automated layer by layer construction of multilayer coated cores by tff |
| WO2015195452A2 (en) * | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Single-pass filtration systems and processes |
| EP4144434B1 (en) * | 2014-06-16 | 2024-04-17 | EMD Millipore Corporation | Single-pass filtration systems and processes |
| EP2957335B1 (en) * | 2014-06-16 | 2020-05-27 | EMD Millipore Corporation | Single-pass filtration systems and processes |
| WO2015195453A2 (en) | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
| KR101938948B1 (ko) | 2014-06-25 | 2019-01-15 | 이엠디 밀리포어 코포레이션 | 밀집한 나권형 필터 엘리먼트, 모듈 및 시스템 |
| JP6615890B2 (ja) * | 2014-08-21 | 2019-12-04 | ザ チャールズ スターク ドレイパー ラボラトリー， インク． | マイクロ流体装置中の望まれない粒子の対流クリアランスを増すためのシステムおよび方法 |
| WO2016033553A1 (en) | 2014-08-29 | 2016-03-03 | Emd Millipore Corporation | Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
| WO2016033546A1 (en) | 2014-08-29 | 2016-03-03 | Emd Millipore Corporation | Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
| CN106188300A (zh) * | 2015-05-07 | 2016-12-07 | 温州市人民医院 | 一种保持胱抑素c抗体-胶乳共价偶联复合物活性的快速纯化方法 |
| DK4108769T3 (da) | 2015-05-29 | 2023-10-09 | Curevac Mfg Gmbh | Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN107320765A (zh) * | 2016-04-29 | 2017-11-07 | 深圳兰度生物材料有限公司 | 一种重组纤维结构胶原蛋白海绵的制备方法 |
| US12226737B2 (en) | 2016-06-09 | 2025-02-18 | Emd Millipore Corporation | Radial-path filter elements, systems and methods of using same |
| BR102017001309A2 (pt) * | 2017-01-23 | 2018-08-14 | Fundação Oswaldo Cruz | vacina recombinante para helmintos em pichia pastoris, e, processos de produção e purificação de proteína como vacina para helmintos |
| WO2019084178A1 (en) * | 2017-10-24 | 2019-05-02 | Cerahelix, Inc. | SYSTEMS AND METHODS FOR MULTI-STAGE FLUID SEPARATION |
| CN107907643A (zh) * | 2017-11-10 | 2018-04-13 | 福建省水产研究所 | 一种测定天然海水中溶解相、纳米相和真溶液相中有机碳和无机氮含量的方法 |
| CN110241012B (zh) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用 |
| EP3794013B1 (en) | 2018-05-17 | 2024-02-21 | CSL Behring AG | Method and system of protein extraction |
| CN113518655B (zh) * | 2019-01-30 | 2023-02-17 | 瑞普利金公司 | 使用径迹蚀刻膜过滤生物流体的方法 |
| CN110607272B (zh) * | 2019-09-23 | 2022-11-01 | 山东甲骨文生物科技有限公司 | 一种哺乳动物细胞培养液的添加剂及细胞培养液 |
| US12285723B2 (en) * | 2019-10-01 | 2025-04-29 | Tetra Laval Holdings & Finance S.A. | Method for filtering a dairy product |
| JP2023502412A (ja) * | 2019-11-20 | 2023-01-24 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 沈殿物からタンパク質を抽出する方法および不純物を沈殿させる方法 |
| CN111018968B (zh) * | 2019-12-16 | 2021-07-27 | 兴盟生物医药(苏州)有限公司 | 一种通过超滤浓缩制备高浓度抗体制剂的方法 |
| KR20230024891A (ko) * | 2020-06-11 | 2023-02-21 | 2세븐티 바이오, 인코포레이티드 | 바이러스 벡터 제조 방법 |
| CN113713621B (zh) * | 2021-08-26 | 2022-08-02 | 杭州纽创生物检测有限公司 | 一种应用于病毒的sptff装置、灌注系统及病毒料液过滤方法 |
| CN116328553A (zh) * | 2022-11-16 | 2023-06-27 | 安徽百奥秘科生物医药研究院有限公司 | 一种过滤膜及一步过滤快速提取核酸装置及提取核酸方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888115A (en) * | 1983-12-29 | 1989-12-19 | Cuno, Incorporated | Cross-flow filtration |
| US4874516A (en) * | 1984-12-29 | 1989-10-17 | Ngk Insulators, Ltd. | A ceramic filter for semi-ultrafiltration |
| US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
| US5256294A (en) * | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| SE470375B (sv) * | 1992-05-07 | 1994-02-07 | Alfa Laval Food Eng Ab | Sätt att erhålla högvärdiga proteinprodukter ur vassle |
| US5356651A (en) * | 1992-12-30 | 1994-10-18 | Pall Corporation | Manufacturing method for producing sterile milk using dynamic microfiltration |
| US5518624A (en) * | 1994-05-06 | 1996-05-21 | Illinois Water Treatment, Inc. | Ultra pure water filtration |
| US5585466A (en) * | 1994-12-06 | 1996-12-17 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Crystals of serum albumin for use in genetic engineering and rational drug design |
| US6268487B1 (en) * | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| GB9807464D0 (en) * | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| AU756832B2 (en) * | 1999-02-22 | 2003-01-23 | Ncsrt, Inc. | Purification of biological substances |
| US6984378B1 (en) * | 1999-02-26 | 2006-01-10 | Pfizer, Inc. | Method for the purification, recovery, and sporulation of cysts and oocysts |
-
2003
- 2003-08-06 JP JP2004568846A patent/JP2006515227A/ja not_active Abandoned
- 2003-08-06 RU RU2005129745/13A patent/RU2005129745A/ru not_active Application Discontinuation
- 2003-08-06 EP EP03816097A patent/EP1601788A4/en not_active Withdrawn
- 2003-08-06 WO PCT/US2003/024529 patent/WO2004076695A1/en not_active Ceased
- 2003-08-06 CN CN03826243.6A patent/CN1759189A/zh active Pending
- 2003-08-06 US US10/635,117 patent/US20040167320A1/en not_active Abandoned
- 2003-08-06 AU AU2003261387A patent/AU2003261387A1/en not_active Abandoned
- 2003-08-06 CA CA002516836A patent/CA2516836A1/en not_active Abandoned
-
2005
- 2005-07-21 US US11/191,280 patent/US20050260672A1/en not_active Abandoned
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010533663A (ja) * | 2007-07-17 | 2010-10-28 | エフ．ホフマン−ラ ロシュ アーゲー | 可変的タンジェンシャルフロー濾過 |
| KR20160138949A (ko) * | 2014-02-17 | 2016-12-06 | 바이엘 악티엔게젤샤프트 | 단백질 용액으로부터의 연속식 완충제 또는 배지 교환을 위한 한외여과 장치 |
| KR102285176B1 (ko) | 2014-02-17 | 2021-08-04 | 바이엘 악티엔게젤샤프트 | 단백질 용액으로부터의 연속식 완충제 또는 배지 교환을 위한 한외여과 장치 |
| JP2017510452A (ja) * | 2014-03-07 | 2017-04-13 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 生物学的生成物の分画のための装置及び方法 |
| US12016873B2 (en) | 2014-05-15 | 2024-06-25 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| US12168022B2 (en) | 2014-05-15 | 2024-12-17 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| US12168021B2 (en) | 2014-05-15 | 2024-12-17 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| US12377114B2 (en) | 2014-05-15 | 2025-08-05 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| JP2021519777A (ja) * | 2018-03-30 | 2021-08-12 | インスメッド インコーポレイテッド | リポソーム医薬品の連続製造方法 |
| JP7460534B2 (ja) | 2018-03-30 | 2024-04-02 | インスメッド インコーポレイテッド | リポソーム医薬品の連続製造方法 |
| US12290600B2 (en) | 2018-03-30 | 2025-05-06 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004076695A1 (en) | 2004-09-10 |
| EP1601788A1 (en) | 2005-12-07 |
| CN1759189A (zh) | 2006-04-12 |
| RU2005129745A (ru) | 2006-03-20 |
| US20040167320A1 (en) | 2004-08-26 |
| CA2516836A1 (en) | 2004-09-10 |
| EP1601788A4 (en) | 2006-11-15 |
| AU2003261387A1 (en) | 2004-09-17 |
| US20050260672A1 (en) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515227A (ja) | 十字流濾過の方法およびそのための装置 | |
| US20050197496A1 (en) | Methods of protein fractionation using high performance tangential flow filtration | |
| EP1991063B1 (en) | Clarification of transgenic milk using depth filtration | |
| CN101076347B (zh) | 用于集成连续生产生物分子的装置和方法 | |
| CA2254871C (en) | Purification of biologically active peptides from milk | |
| Arunkumar et al. | Investigation of single-pass tangential flow filtration (SPTFF) as an inline concentration step for cell culture harvest | |
| JP7737374B2 (ja) | 透析濾過緩衝液を用いて増強したウイルス濾過 | |
| CA2495890A1 (en) | Model for microfiltration of poly-disperse suspensions | |
| CN101027080A (zh) | 用高效切向流过滤进行蛋白质分级的方法 | |
| KR20240042237A (ko) | 결합 및 용리 크로마토그래피 정제의 부피 부하 유량을 감소시키고 생산성을 증가시키기 위한 인-라인 생성물 농축 | |
| Ulber et al. | Membranes for protein isolation and purification | |
| Kumpalume et al. | Chromatography: the high-resolution technique for protein separation | |
| Sartorius | Roland Ulber and Kerstin Plate University of Hannover, Hannover, Germany Oskar-Werner Reif and Dieter Melzner Sartorius AG, Göttingen, Germany |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060807 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060807 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20070305 |